Article Text

Download PDFPDF
Current Academic Clinical Trials in Ovarian Cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009
  1. Edward L. Trimble, MD*,
  2. Michael J. Birrer, MD,
  3. William J. Hoskins, MD,
  4. Christian Marth, MD, PhD§,
  5. Ray Petryshyn, PhD*,
  6. Michael Quinn, MD,
  7. Gillian M. Thomas, MD,
  8. Henry C. Kitchener, MD**,
  9. for the Gynecologic Cancer Intergroup/National Cancer Institute Writing Committeea
  1. *NCI, National Institutes of Health, Bethesda, MD;
  2. Massachusetts General Hospital, Boston, MA;
  3. Memorial Sloan-Kettering Cancer Center, New York, NY;
  4. §University Hospital Innsbruck, Innsbruck, Austria;
  5. University of Melbourne, Melbourne, Victoria, Australia;
  6. Sunnybrook Odette Cancer Center, Toronto, Ontario, Canada; and
  7. **University of Manchester, Manchester, United Kingdom.
  1. aGCIG/NCI Writing Committee members: Carol Aghajanian, MD, MSKCC, New York, NY (GOG); David S. Alberts, MD, University of Arizona Cancer Center, Tucson, AZ (GOG, SWOG); Deborah Armstrong, MD, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD (GOG, SWOG); M.J.B. (as above, GOG); Jubilee Brown, MD, University of Texas MD Anderson Cancer Center, Houston, TX (GOG); Robert L. Coleman, MD, University of Texas MD Anderson Cancer Center, Houston, TX, (GOG, SWOG); Nicoletta Colombo, MD, European Institute of Oncology, Milan, Italy (EORTC, GOG, MaNGO); Elizabeth Eisenhauer, MD,NCIC CTG, Kingston, Ontario, Canada, (NCIC CTG); Michael Friedlander, MD, PhD University of New South Wales, Sydney, New South Wales, Australia (ANZGOG); Keiichi Fujiwara, MD, PhD, Saitama Medical University, Saitama-Ken, Japan (GOG, JGOG); W.J.H. (as above, GOG), Sally Hunsberger, PhD, NCI, NIH, Bethesda, MD; H.K. (as above, UK MRC/NCRI); Stan Kaye, MD, Royal Marsden Hospital, London, UK (SGCTG); Jonathan A. Ledermann, MD, University College London, London, UK (MRC/NCRI); Susanna Lee, MD, Massachusetts General Hospital, Boston, MA (ACRIN); Katherine Look, MD, Eli Lilly and Company, Indianapolis, IN; Robert Mannel, MD, University of Oklahoma, Oklahoma City, OK (GOG); C.M. (as above, AGO-Austria), Iain A. McNeish, MD, PhD, Imperial College, London, UK; Lori Minasian, MD, NCI,NIH, Bethesda, MD, Amit Oza, MD, Princess Margaret Hospital, Toronto, Ontario, Canada (NCIC CTG); Jim Paul, PhD, Cancer Research UK Clinical Trials Unit, Glasgow, Scotland, UK (SCGTG); Andres Poveda, MD, Instituto Valenciano de Oncologia, Valencia, Spain (GEICO); Eric Pujade-Lauraine, MD,Hôpital Hotel-Diu, Paris,France (GINECO); M.Q. (as above, ANZGOG); Mason Schoenfeldt, EMMES Corporation, Rockville,MD; Ann Marie Swart, MD, Medical Research Council, London, UK (MRC/NCRI); G.M.T. (as above, ACRIN, GOG), E.L.T. (as above), Vivian von Gruenigen, MD, Summa Health Systems, Akron, OH (GOG); Lari Wenzel, PhD, University of California Irvine, Orange, CA (GOG).
  2. Address correspondence and reprint requests to Edward L. Trimble, MD, National Cancer Institute, 6130 Executive Blvd, Suite 7075, MSC 7436, Bethesda, MD 20892-7436. E-mail: tt6m{at}


Objective: To review the current status of large phase academic clinical trials for women with ovarian cancer, address cross-cutting issues, and identify promising areas for future collaboration.

Methods: In May 2009, the Gynecologic Cancer Intergroup, which represents 19 Cooperative Groups conducting trials for women with gynecologic cancer, and the US National Cancer Institute convened a Clinical Trials Planning Meeting.

Results: The topics covered included the impact of new developments in cancer biology upon molecular targets and novel agents, pharmacogenomics, advances in imaging, the potential benefit of diet and exercise to reduce the risk of recurrence, academic partnership with industry, statistical considerations for phases 2 and 3 trials, trial end points, and symptom benefit and health-related quality-of-life issues. The clinical trials discussed spanned the spectrum of ovarian cancer from initial diagnosis, staging, and cytoreductive surgery to consolidation chemotherapy, and treatment of recurrent disease.

Conclusions: Ongoing and effective collaboration with industry, government, and patients aims to ensure that the most important scientific questions can be answered rapidly. We encourage women with ovarian cancer and their oncologists to consider participation in the academic clinical trials conducted by the member groups of the Gynecologic Cancer Intergroup.

  • Ovarian cancer
  • Clinical trials
  • Treatment

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.